Analysts Set Boston Scientific Corporation (NYSE:BSX) Price Target at $118.04

Shares of Boston Scientific Corporation (NYSE:BSX) have received a consensus recommendation of “Buy” from the twenty-six brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, twenty-two have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $118.1667.

Several brokerages have recently weighed in on BSX. Leerink Partnrs upgraded Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. Needham & Company LLC reaffirmed a “buy” rating and set a $121.00 target price on shares of Boston Scientific in a research report on Friday, September 19th. Raymond James Financial boosted their target price on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Boston Scientific in a research report on Thursday, July 24th. Finally, UBS Group boosted their target price on Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, July 24th.

Insider Buying and Selling

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director directly owned 2,081 shares of the company’s stock, valued at $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $18,397,457 over the last ninety days. 0.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BSX. Norges Bank acquired a new position in Boston Scientific during the second quarter valued at $2,089,937,000. Edgewood Management LLC acquired a new position in Boston Scientific in the 2nd quarter worth about $746,655,000. Bessemer Group Inc. increased its position in Boston Scientific by 14,391.8% in the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock worth $313,618,000 after purchasing an additional 2,899,653 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Boston Scientific by 11,720.3% during the 1st quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider’s stock worth $260,057,000 after purchasing an additional 2,556,078 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Boston Scientific by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after purchasing an additional 2,545,381 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Up 0.3%

Shares of Boston Scientific stock opened at $98.02 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market cap of $145.24 billion, a price-to-earnings ratio of 58.35, a price-to-earnings-growth ratio of 2.35 and a beta of 0.65. The business has a fifty day simple moving average of $104.03 and a 200-day simple moving average of $102.03. Boston Scientific has a fifty-two week low of $80.64 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company’s revenue was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts forecast that Boston Scientific will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.